Meridian Bioscience
Meridian Bioscience Fiscal Q2 Revenues Up 49 Percent
Despite the overall revenue increase, revenues from Meridian's diagnostic segment were down 9 percent.
NIH RADx Program Awards $29.3M to Increase SARS-CoV-2 Testing Capacity
The contracts are for two lateral flow rapid antigen tests, a laboratory-based test to detect and identify SARS-CoV-2 variants, and a rapid RT-PCR test.
GenomeWeb Index Falls Again in March, Led by 29 Percent Decline in Adaptive Biotech Stock
The GenomeWeb Index underperformed the Dow Jones and the Nasdaq, but outperformed the Nasdaq Biotechnology Index last month.
Meridian Withdraws Emergency Use Authorization Application to FDA for Coronavirus MDx Test
The company, which had received a request from the FDA for more information on the test, is planning additional studies before resubmitting the application.